128 results on '"Abraham Majluf-Cruz"'
Search Results
102. Lamivudine-induced pure red cell aplasia
- Author
-
Abraham Majluf-Cruz, Sandra Treviño-Perez, Germán Luna-Castaños, Leopoldo Nieto-Cisneros, and Mario Santoscoy
- Subjects
medicine.medical_specialty ,Anti-HIV Agents ,Anemia ,Lamivudine ,Pure red cell aplasia ,Hematology ,Biology ,Red-Cell Aplasia, Pure ,medicine.disease ,Gastroenterology ,Hemolysis ,medicine.anatomical_structure ,Reticulocyte ,hemic and lymphatic diseases ,Internal medicine ,Immunology ,medicine ,Humans ,Bone marrow ,Hemoglobin ,Aplastic anemia ,medicine.drug - Abstract
The aim of this report is to describe five patients with lamivudine-induced pure red cell aplasia, an association not previously described. We describe patients with unresponsive anemia in whom a complete study including blood cell counts, reticulocyte counts, hemolysis tests, and bone marrow aspiration was performed. Pure red cell aplasia was considered when anemia was associated with normal leukocyte and platelet counts with a corrected reticulocyte count below 1% and less than 5% bone marrow erythroid progenitors in the absence of positive hemolysis tests. Complete remission was considered when bone marrow erythroid progenitors were at least 16%. Five male patients had pure red cell aplasia with a median age of 32 years (range 29 to 37 years). Before lamivudine, they had hemoglobin11.8 g/dl without transfusion requirements. After receiving the drug, hemoglobin dropped to 5.2 g/dl (4.3 to 6.1 g/dl) with high transfusion requirements and mean bone marrow erythroid progenitors of 1.84% (0 to 4%). Withdrawal of lamivudine was attempted to confirm the diagnosis. Seven weeks after stopping lamivudine, hemoglobin rose up to 12.8 g/dl (11 .3 to 13.8 g/dl) and bone marrow erythroid progenitors increased up to 25.6% (21 to 40%) without transfusion requirements. Lamivudine-induced pure red cell aplasia may be a cause of anemia unresponsive to conventional treatment in AIDS. Since lamivudine use in Mexico has been relatively short, we expect more cases to appear in the future. more...
- Published
- 2000
- Full Text
- View/download PDF
103. Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation
- Author
-
Hector Mayani, Elba Reyes-Maldonado, Ethel García-Latorre, Jaime García-Chávez, Abraham Majluf-Cruz, José R. Borbolla-Escoboza, Miriam García-Ruiz Esparza, Jorge Vela-Ojeda, Laura Montiel-Cervantes, and Perla Granados-Lara more...
- Subjects
Male ,Time Factors ,Transplantation Conditioning ,Cyclophosphamide ,medicine.medical_treatment ,Graft vs Host Disease ,chemical and pharmacologic phenomena ,Disease ,Hematopoietic stem cell transplantation ,Biology ,T-Lymphocytes, Regulatory ,immune system diseases ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Transplantation, Homologous ,IL-2 receptor ,L-Selectin ,Graft Survival ,Hematopoietic Stem Cell Transplantation ,Interleukin-2 Receptor alpha Subunit ,FOXP3 ,Forkhead Transcription Factors ,Cell Biology ,Hematology ,Natural killer T cell ,Flow Cytometry ,Survival Analysis ,Hematopoietic Stem Cell Mobilization ,Killer Cells, Natural ,surgical procedures, operative ,Immunology ,Methotrexate ,Female ,Busulfan ,Developmental Biology ,medicine.drug - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for some hematological diseases; however, graft-versus-host disease (GVHD) is still one of the most important and deleterious complications. Regulatory T cells and iNKT cells can decrease the incidence and severity of GVHD, while preserving the graft-versus-tumor response. In order to analyze the relationship between the transfused dose of these cells, the presence of GVHD and survival, 15 normal donors and 15 patients with hematological diseases who underwent allogeneic HSCT from HLA-identical siblings were studied. The mobilization and infused doses of valpha24-vbeta11(iNKT cells) lymphocytes and CD4+CD25+FoxP3+, CD4+CD25+FoxP3+CD62L+, regulatory T cells were analyzed. All patients were conditioned with busulfan and cyclophosphamide and received cyclosporine and methotrexate as GVHD prophylaxis. iNKT and FoxP3 cells were mobilized after G-CSF administration. Acute GVHD was present in 9 of 15 (60%) and cGVHD in 7 of 13 (54%) patients. Patients who received a dose0.6 x 10(6)/kg of iNKT cells and4 x 10(6)/kg of FoxP3 had better disease-free survival and overall survival. Individuals transfused with1.1 x 10(6)/kg of FoxP3+ CD62L+ Treg cells had better overall survival. In conclusion, iNKT and Treg cells are mobilized with G-CSF in healthy donors and the dose of iNKT cells and FoxP3 and CD62L+ regulatory T cells is of clinical importance in human HSCT. more...
- Published
- 2009
104. Fibrinogen is associated with silent myocardial ischaemia in type 2 diabetes mellitus
- Author
-
Jorge Molina-Padilla, Alfonso Aleman-Mireles, Mauro Francisco Pacheco-Carrasco, Lilia M. Jimenez-Ceja, Abraham Majluf-Cruz, Rodolfo Guardado-Mendoza, Guillermo Villa-Godinez, Jorge Escobedo-de la Peña, and Arnoldo Aguayo-Godinez more...
- Subjects
Male ,medicine.medical_specialty ,education ,Diastole ,Myocardial Ischemia ,Urine ,Type 2 diabetes ,Fibrinogen ,chemistry.chemical_compound ,Internal medicine ,mental disorders ,Medicine ,Humans ,business.industry ,Cholesterol ,fungi ,Albumin ,Type 2 Diabetes Mellitus ,General Medicine ,Middle Aged ,medicine.disease ,Mean blood pressure ,Cross-Sectional Studies ,chemistry ,Diabetes Mellitus, Type 2 ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Objective ― Because traditional risk factors only partially explain coronary events, it is necessary to search for new ones like fibrinogen which has been related with coronary disease in healthy middle-aged adults.We attempted to determine the impact of fibrinogen on silent myocardial ischaemia (SMI) in diabetic patients. Methods and results ― In a cross-sectional study, 134 type 2 diabetes patients with no history of cardiovascular disease were assessed for SMI.A personal history and physical evaluation of each patient was conducted as well as evaluation of cholesterol, glucose, fibrinogen, blood cell counts, glycated haemoglobin, urine albumin quantification, and urinalysis.A modified Bruce test was performed on all study participants to evaluate the presence of SMI. Results ― Eleven patients had SMI (8.2%) that was associated with systolic, diastolic and mean blood pressure, hypertension, and fibrinogen.The correlation coefficient was obtained for quintiles of fibrinogen with the percentage of patients with SMI in that quintile (r = 0.97; 95% = 0.66-0.99). Fibrinogen levels were associated with SMI.A receiver-operator curve analysis showed that the cutoff value for fibrinogen to predict SMI was 400 mg/dL (82% sensitivity, 81% specificity). A cutoff value of 306 mg/dL of fibrinogen would rule in the diagnosis of SMI (100% sensitivity, 17% specificity), while fibrinogen cutoff of 682 mg/dL would rule out SMI (100% specificity, 9% sensitivity). Conclusions ― Fibrinogen strongly predicts SMI in diabetic patients and may identify individuals with high cardiovascular risk. Fibrinogen should be evaluated in diabetic patients for a more accurate cardiovascular evaluation. more...
- Published
- 2009
105. [The quality control in the coagulation laboratory]
- Author
-
Adriana Aurelia, Ruiz-de-Chávez-Ochoa, Evangelina, Núñez-Pérez, Beatriz, Muñoz-Muñoz, and Abraham, Majluf-Cruz
- Subjects
Quality Control ,Humans ,Blood Coagulation Tests ,Diagnostic Errors - Abstract
This is a broad review of sources of error in the coagulation tests, all of which must be considered, evaluated and supervised to improve their quality. The analytical result of a laboratory examination is a scientific fact and has no medical meaning as such. It must be interpreted to become a medical finding. Recent improvement in equipment, reagents, and the fact that hemophilic and thrombotic events are considered the main causes of death are the principal reasons to prepare this article. The internal quality control program considers this fact because its beginning starts when the physician makes the request to the lab; moreover, the clinical interpretation of the results of the laboratory represents the end of the cycle. Outcome of clinical test in hemostasis is critically dependent upon the quality of the sample, the method, the instruments, the reagents and the personnel involved in the performance of the test. Use of high quality blood collection procedures and an awareness of preanalytic errors are presented to lead to quality outcomes. Today, performance of internal and external quality control programs is obligatory. more...
- Published
- 2009
106. [Factor VIII activity among young Mexican patients with acute myocardial infarction]
- Author
-
Abraham, Majluf-Cruz, Manuel, Moreno-Hernández, Noemí, Martínez-Esquivel, Adriana Aurelia, Ruiz de Chávez-Ochoa, Erika, Coria-Ramírez, Rosario, Monroy-García, Jorge, Vela-Ojeda, Jaime, García-Chávez, Marcelo, Basave-Rojas, and Miguel Angel, Villasís-Keeverd more...
- Subjects
Adult ,Male ,Cross-Sectional Studies ,Factor VIII ,Risk Factors ,Myocardial Infarction ,Humans ,Female ,Middle Aged ,Mexico - Abstract
Atherothrombotic disease is the leading cause of death worldwide. Most casualties are due to acute myocardial infarction (AMI). Patients younger than 45 years account for 5-10% of AMI cases. These patients generally do not display typical atherothrombotic risk factors.Our cross-sectional study included adult patients under 45; men and women with AMI were included. A control group of healthy individuals matched for age, sex, and blood group was included to determine the role of several atherothrombotic risk factors on AMI. One hundred and sixty patients were included, the control group was comprised by 77 males (m) and 83 females (f)Our results indicate that 25% of patients (23 m and 18 f) had increased FVIII compared with 8.8% of control subjects. Mean FVIII activity for patients and controls was 134 mg/dl (95%CI=114) vs. 118 mg/dl (95%CI=128-140), respectively (p=0.001). Prevalence of elevated FVIII was higher than the one found for hypertension or diabetes mellitus. HDL cholesterol was higher among patients than controls. Quantitative variables associated with AMI were high FVIII activity, blood monocyte count and HDL cholesterol.Classical atherothrombotic risk factors do not fully explain AMI events in the young. High levels of FVIII activity is a moderate but common risk factor in young people suffering AMI. more...
- Published
- 2008
107. Activated protein C resistance and factor V Leiden in Mexico
- Author
-
Irma Isordia-Salas, Jaime García-Chávez, Irma Molina-Ávila, Jorge Vela-Ojeda, Rosario Monroy-García, Norma Angélica Corona de la Peña, Karim Majluf-Cruz, Adriana Aurelia Ruiz-de-Chávez-Ochoa, Rodolfo Guardado-Mendoza, Abraham Majluf-Cruz, Manuel Moreno-Hernández, and Florencia Vargas-Vorackova more...
- Subjects
Adult ,Male ,congenital, hereditary, and neonatal diseases and abnormalities ,Adolescent ,Hereditary thrombophilia ,hemic and lymphatic diseases ,medicine ,Factor V Leiden ,Prevalence ,Humans ,cardiovascular diseases ,Mexico ,Activated Protein C Resistance ,Aged ,Genetics ,biology ,business.industry ,Factor V ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,female genital diseases and pregnancy complications ,Mexican population ,Cross-Sectional Studies ,biology.protein ,Female ,Factor V Leiden mutation ,Activated protein C resistance ,business - Abstract
A common cause of hereditary thrombophilia is activated protein C resistance (APCR), and most cases result from factor V Leiden mutation. An APCR phenotype without association with factor V Leiden has been described. This transversal, observational, nonrandomized study evaluated these 2 phenomena in healthy indigenous and mestizo Mexican subjects (n = 4345), including 600 Mexican natives. No indigenous subjects had APCR, but 82 mestizo subjects did. After retesting, 50 subjects had a negative test. The remaining 32 subjects had factor V Leiden, giving a 0.85% prevalence of factor V Leiden in the mestizo Mexican population. Only 31% of APCR carriers had factor V Leiden. These results show a very low prevalence of APCR and factor V Leiden in Mexico. Except for factor V Leiden, there are no other mutations in the factor V gene responsible for the APCR phenotype. Acquired APCR is nearly twice as prevalent as the inherited variant. more...
- Published
- 2007
108. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor
- Author
-
E Sanchez-Cortés, Abraham Majluf-Cruz, Hector Mayani, M. A. García-Ruiz Esparza, Laura Montiel-Cervantes, Y. Padilla-González, Jorge Vela-Ojeda, Jaime García-Chávez, and Elba Reyes-Maldonado
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Biopsy ,Antineoplastic Agents ,Gastroenterology ,Disease-Free Survival ,Risk Factors ,Internal medicine ,medicine ,Humans ,Multiple myeloma ,Aged ,Proportional Hazards Models ,Chemotherapy ,Hematology ,Performance status ,medicine.diagnostic_test ,business.industry ,Proportional hazards model ,Amyloidosis ,Remission Induction ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Surgery ,B symptoms ,Adipose Tissue ,Regression Analysis ,Female ,medicine.symptom ,business ,Multiple Myeloma - Abstract
Several prognostic factors have been recognized in patients with multiple myeloma (MM). Among the most important are: the serum levels of β2-microglobulin, albumin, and LDH; the labeling index; and an abnormal karyotype. Patients with amyloidosis (AL) have poor prognosis; however, little is known concerning the prognostic significance of AL associated to MM. In 201 consecutive patients with de novo MM, we performed a fat-pad biopsy needle aspiration (FPBNA) that was stained with Congo red. Sixty eight (34%) patients had AL and a poorer prognosis disease: lower performance status, presence of B symptoms, higher LDH and calcium values, and worse response to chemotherapy. Cox regression model for overall survival detected three variables having independent prognostic significance: the presence of AL (RR = 3.4, P < 0.004), serum albumin levels more...
- Published
- 2007
109. Interaction of the protein C activation peptide with platelets
- Author
-
Pedro Hernández Cruz, Margarito Martínez Cruz, Ruth Martínez-Cruz, Abraham Majluf-Cruz, Félix Córdoba Alva, Alejandro Ruiz-Argüelles, María del Socorro Pina Canseco, Edgar Zenteno, Eduardo Pérez-Campos, and Jael Lopez-Martínez more...
- Subjects
Blood Platelets ,Platelet Aggregation ,Molecular Sequence Data ,Peptide ,Receptors, Cell Surface ,Biochemistry ,Cell membrane ,Thrombin ,Zymogen ,medicine ,Platelet ,Amino Acid Sequence ,Receptor ,Peptide sequence ,chemistry.chemical_classification ,Enzyme Precursors ,Chemistry ,General Medicine ,Platelet Activation ,medicine.anatomical_structure ,Calcium ,Receptors, Thrombin ,Oligopeptides ,Protein C ,Platelet Aggregation Inhibitors ,Biotechnology ,medicine.drug - Abstract
The peptide NH(2)-DTEDQEDQVDPR-COOH is released during activation of protein C zymogen. We measured the effect of a synthetic peptide with an amino acid sequence similar to that of the natural peptide on platelets from healthy individuals using platelet aggregometry. We found that this synthetic peptide inhibits platelet aggregation induced by thrombin; furthermore, it diminishes mobilization of intraplatelet calcium. Molecular docking showed weak interaction between the synthetic peptide and thrombin. Our findings suggest that this synthetic peptide may interact with a receptor located on the platelet cell membrane. more...
- Published
- 2007
110. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis
- Author
-
Jaime García-Chávez, Abraham Majluf-Cruz, Laura Montiel-Cervantes, Miriam García-Ruiz Esparza, and Jorge Vela-Ojeda
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Salvage therapy ,Gastroenterology ,Anti-CD20 ,Antibodies, Monoclonal, Murine-Derived ,Refractory ,Recurrence ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Adverse effect ,Chronic ITP ,Aged ,Salvage Therapy ,Purpura, Thrombocytopenic, Idiopathic ,Hematology ,business.industry ,Platelet Count ,Refractory ITP ,Remission Induction ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,medicine.disease ,Thrombocytopenic purpura ,Surgery ,Monoclonal ,Rituximab ,Female ,Original Article ,business ,Immunosuppressive Agents ,medicine.drug ,Follow-Up Studies - Abstract
The aim of this study was to evaluate the long-term response to rituximab in patients with chronic and refractory immune thrombocytopenic purpura (ITP). Adults with ITP fail to respond to conventional therapies in almost 30% of cases, developing a refractory disease. Rituximab has been successfully used in these patients. We used rituximab at 375 mg/m2, IV, weekly for a total of four doses in 18 adult patients. Complete remission (CR) was considered if the platelet count was100 x 10(9)/l, partial remission (PR) if platelets were50 x 10(9)/l, minimal response (MR) if the platelet count was30 x 10(9)/l and50 x 10(9)/l, and no response if platelet count remained unchanged. Response was classified as sustained (SR) when it was stable for a minimum of 6 months. Median age was 43.5 years (range, 17 to 70). Median platelet count at baseline was 12.5 x 10(9)/l (range, 3.0 to 26.3). CR was achieved in five patients (28%), PR in five (28%), MR in four (22%), and two patients were classified as therapeutic failures (11%). Two additional patients were lost to follow-up. The median time between rituximab therapy and response was 14 weeks (range, 4 to 32). SR was achieved in 12 patients (67%). There were no severe adverse events during rituximab therapy. During follow-up (median, 26 months; range, 12 to 59), no other immunosuppressive drugs were used. In conclusion, rituximab therapy is effective and safe in adult patients with chronic and refractory ITP. Overall response rate achieved is high, long term, and with no risk of adverse events. more...
- Published
- 2007
111. Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope
- Author
-
Abraham Majluf-Cruz, Tatiana Gazarian, Karlen Gazarian, Merrill J. Rowley, and Yadira Palacios-Rodríguez
- Subjects
Microbiology (medical) ,Population ,Molecular Sequence Data ,Enzyme-Linked Immunosorbent Assay ,HIV Infections ,Biopanning ,Gp41 ,Microbiology ,Epitope ,Mice ,Antigen ,Peptide Library ,Animals ,Humans ,Amino Acid Sequence ,education ,Molecular Biology ,education.field_of_study ,Linear epitope ,biology ,Mimotope ,Immunodominant Epitopes ,Virology ,HIV Envelope Protein gp41 ,Peptide Fragments ,Mice, Inbred C57BL ,Immunoglobulin G ,biology.protein ,HIV-1 ,Female ,Immunization ,Antibody ,Sequence Alignment - Abstract
Early diagnosis and prevention of human immunodeficiency virus type-1 (HIV-1) infection, which remains a serious public health threat, is inhibited by the lack of reagents that elicit antiviral responses in the immune system. To create mimotopes (peptide models of epitopes) of the most immunodominant epitope, CSGKLIC, that occurs as a loop on the envelope gp41 glycoprotein and is a key participant in infection, we used phage-display technology involving biopanning of large random libraries with IgG of HIV-1-infected patients. Under the conditions used, library screening with IgG from patient serum was directed to the CSGKLIC epitope. Three rounds of selection converted a 12 mer library of 10 9 sequences into a population in which up to 79% of phage bore a family of CxxKxxC sequences (“x” designates a non-epitope amino acid). Twenty-one phage clones displaying the most frequently selected peptides were obtained and were shown to display the principal structural (sequence and conformational), antigenic and immunogenic features of the HIV-1 immunodominant loop-epitope. Notably, when the mixture of the phage mimotopes was injected into mice, it induced 2- to 3-fold higher titers of antibody to the HIV-1 epitope than could be induced from individual mimotopes. The described approach could be applicable for accurately reproducing HIV-1 epitope structural and immunological patterns by generation of specialized viral epitope libraries for use in diagnosis and therapy. more...
- Published
- 2006
112. Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers
- Author
-
Lisneth Osiris Matias-Aguilar, Karim Majluf-Cruz, Erika Coria-Ramirez, Abraham Majluf-Cruz, Sandra Treviño-Perez, Ignacio Pineda-del Aguila, Julio César López-Armenta, Norma Corona de la Peña, and Adriana Ruiz de Chavez-Ochoa more...
- Subjects
Adult ,Blood Platelets ,Male ,Ticlopidine ,Platelet aggregation ,Platelet Aggregation ,Platelet Glycoprotein GPIIb-IIIa Complex ,Pharmacology ,GpIIb/IIIa ,Pharmacotherapy ,Reference Values ,Medicine ,Humans ,Platelet ,cardiovascular diseases ,Platelet activation ,Aspirin ,business.industry ,Lysine ,Hematology ,General Medicine ,Middle Aged ,Clopidogrel ,digestive system diseases ,surgical procedures, operative ,Lysine acetylsalicylate ,Drug Therapy, Combination ,Female ,business ,Platelet Aggregation Inhibitors ,circulatory and respiratory physiology ,medicine.drug - Abstract
Platelet activation contributes to thrombotic events in cardiovascular disease. Acetylsalicylic acid (ASA) is used in combination with clopidogrel to reduce cardiovascular events. Lysine acetylsalicylate (L-ASA), also inhibits platelet activation with fewer gastrointestinal side effects than ASA. Dual therapy with L-ASA and clopidogrel may result in an antiplatelet effect with fewer side effects. We compared the antiplatelet effect of combined ASA/clopidogrel versus L-ASA/clopidogrel in healthy subjects. Fourteen volunteers (seven men and seven women, aged 25-45 years) received antiplatelet therapy during 14-day periods in the following sequence: 75 mg ASA; 160 mg L-ASA; 75 mg clopidogrel; 160 mg L-ASA plus 75 mg clopidogrel, and 75 mg ASA plus 75 mg clopidogrel. We evaluated platelet aggregation and glycoprotein IIb/IIIa activation. Our results show that administration of L-ASA/clopidogrel is as effective as ASA/clopidogrel combination. more...
- Published
- 2006
113. [Clinical characteristics and follow-up of patients with AIDS and acute abdominal pain]
- Author
-
Eduardo, Ferat-Osorio, Gilberto, Guzmán-Valdivia Gómez, Lourdes, Rosales Blasco, Sandra, Treviño-Perez, Leopoldo, Nieto-Cisneros, and Abraham, Majluf-Cruz
- Subjects
Adult ,Male ,Acquired Immunodeficiency Syndrome ,Postoperative Complications ,Acute Disease ,Humans ,Female ,Middle Aged ,Emergency Treatment ,Abdominal Pain ,Follow-Up Studies - Abstract
Abdominal symptoms frequently affect patients with AIDS. Acute abdominal pain is a diagnostic challenge that may require elective or urgent surgical treatment, although information about the latter is scarce. In this study we analyzed the clinical findings and follow-up of acute abdominal pain complicating patients with AIDS. In a two-year period, we collected several variables from patients with AIDS and acute abdominal pain: demographic, laboratory, clinical symptoms, initial diagnosis, surgical findings, post-surgical and histopathological diagnosis and post-surgical complications. From 232 hospitalized patients, 34 had acute abdominal pain: 32 male and 2 women (median age = 32 years; range 26 to 58 years). Twenty-two patients required surgical treatment. Eight patients had a post-surgical complication; in five of them, six surgical re-interventions were performed. Three deaths occurred in the 30-day period after surgery. Survival for patients conservatively treated was 4 months (1 to 17 months), vs. 6.5 months (1 to 20 months) in the surgically treated group. Physicians should be aware about the several diagnostic possibilities of acute abdominal pain complicating patients with AIDS. Delay of surgery in these patients may be lethal. Surgery has an important role in the integral treatment of patients with AIDS. more...
- Published
- 2005
114. Polyamines inhibit both platelet aggregation and glycoprotein IIb/IIIa activation
- Author
-
Norma A. Corona-de-la-Peña, Salvador Uribe-Carvajal, Lisnet Matias-Aguilar, Guadalupe Montiel-Manzano, Abraham Majluf-Cruz, and Rehotbeverly Barrientos-Rios
- Subjects
Pharmacology ,Blood Platelets ,Dose-Response Relationship, Drug ,Platelet Aggregation ,Fibrinogen receptor ,Spermidine ,Biogenic Polyamines ,Fibrinogen binding ,Spermine ,Platelet Glycoprotein GPIIb-IIIa Complex ,In Vitro Techniques ,Platelet membrane glycoprotein ,Platelet Activation ,Molecular biology ,chemistry.chemical_compound ,chemistry ,Biochemistry ,Putrescine ,Humans ,Cardiology and Cardiovascular Medicine ,Glycoprotein IIb/IIIa ,Polyamine ,Platelet Aggregation Inhibitors - Abstract
Platelet aggregation is inhibited by the polyamines putrescine, spermidine, and spermine. To date, the mechanism of action has not been clearly identified. Evidence suggests that polyamines may interact with the fibrinogen receptor (GP IIb/IIIa), interfering with platelet-platelet attachment. The effect of polyamines on human platelet aggregation and GP IIb/IIIa activation was evaluated. For the aggregation experiments, platelets were obtained from heparin- or citrate-collected blood. Our results indicate that the polyamines putrescine, spermidine, and spermine cause a dose-dependent inhibition of ADP- or collagen-mediated platelet aggregation with an order of potency spermine>spermidine>putrescine. In addition, spermine arrests or inhibits thrombin-, epinephrine-, arachidonate-, or ristocetin-induced platelet aggregation. Expression of platelet membrane glycoproteins IIb, IIIa, and IX is not reduced by polyamines. However, spermine inhibits the ADP- or thrombin-induced activation of GP IIb/IIIa. It is concluded that the final step in aggregation, common to all agonists, ie, fibrinogen binding to GP IIb/IIIa, is inhibited by spermine through inhibition of the agonist-induced activation of GP IIb/IIIa that precedes fibrinogen-ligand binding. more...
- Published
- 2005
115. [A new thrombophilia risk factor: the increase of plasma factor VIII]
- Author
-
Julia, Hernández-Jerónimo, Eduardo, Pérez-Campos, Cuauhtémoc, Matadamas, and Abraham, Majluf-Cruz
- Subjects
Factor VIII ,Risk Factors ,Humans ,Thrombophilia ,Thrombosis - Abstract
Factor VIII (FVIII) is key component of the fluid phase of the blood coagulation system. Recent evidence suggests a direct relationship between high plasma levels of FVIII and an increased risk for arterial and venous thrombosis. Thus material reviews the most important clinical and epidemiological evidence about this prothrombotic association. Main function of FVIII is to activate FX functioning as a cofactor for activated FIX in the presence of phospholipids and calcium. Since its deficiency has been historically associated with a hemorrhagic disease (namely hemophilia A), it was never studied its role in thrombosis. In order to explain the association FVIII and thrombosis, defects in its synthesis that increase its plasma concentration as well as postranslational modifications that allow a higher activity, have been proposed. Since 1977 it was suggested that increased plasma concentrations of FVIII and thrombosis may be associated. Shortly after, several other studies confirmed this association. Indeed, patients with stroke of acute myocardial infarction having high plasma levels of FVIII have a shorter survival. On the other hand, deep venous thrombosis is more frequent in patients with high plasma levels of FVIII. This rise in plasma FVIII concentration is also associated with recurrent venous thrombosis. The increment of plasma FVIII concentration is not due to an acute phase reaction. Plasma concentrations of FVIII above 100-150 IU/dL increase 3-fold the risk of thrombosis while concentrations above 150 IU/dL increase the the same risk 6-fold. While it is established the real importance of FVIII as a cause of thrombosis, every patient at risk of thrombosis must have a quantification of this factor. Evaluation of plasma FVIII concentration must be performed in patients with suspected thrombophilia since there is evidence that shows that high plasma FVIII levels is an independent thrombophilic risk factor. There are not effective therapeutic interventions able to normalize the high concentrations of FVIII. Therefore, appropriate prophylaxis during high thrombosis risk clinical episodes is the best alternative for the patient. more...
- Published
- 2003
116. [National evaluation of the diagnosis of activated protein C resistance]
- Author
-
Guadalupe, Montiel-Manzano, Aurora, de la Peña-Díaz, Abraham, Majluf-Cruz, Gabriela, Cesarman-Maus, Norma, Corona-de la Peña, Donají, Cruz-Cruz, Elizabeth, Gaminio, Carlos, Martínez-Murillo, Teresa, Mayagoitia, Enrique, Miranda-Peralta, Teresita, Poblete, Sandra, Quintana-Martínez, Raúl, Ramírez, Daniel, Razo, Adriana, Ruiz de Chávez-Ochoa, Virginia Adriana, Reyes-Núñez, Rosario, Salazar, Guadalupe Virginia, Vicencio-Santiago, Rosario, Villa, and Aurelia Virginia, Reyes-Núñez more...
- Subjects
Quality Control ,Genotype ,DNA Mutational Analysis ,Factor V ,Mass Screening ,Thrombophilia ,Laboratories ,Mexico ,Polymerase Chain Reaction ,Activated Protein C Resistance - Abstract
Thrombophilia or prothrombotic state appears when activation of blood hemostatic mechanisms overcomes the physiological anticoagulant capacity allowing a thrombotic event. Thrombosis is the leading worldwide mortality cause and due to its high associated morbidity and mortality, it should be insisted in the opportune identification of a thrombophilic state. The study of thrombophilia identifies individuals at high risk for thrombosis. This meeting was conceived first to analyze the current status of the diagnosis of thrombophilia in Mexico and second to create the base for a national consensus for thrombophilia screening and for the establishment of a national center for laboratory reference and quality control for thrombophilia. Since searching of activated protein C resistance (APCR) and FV Leiden seem to have priority either in the clinical setting and in public health services, it was decided to start with these two abnormalities as a model to analyze the current status of thrombophilia diagnosis in the clinical laboratory. At this time, several thrombophilic abnormalities have been described however, APCR remains the most important cause of thrombophilia, accounting for as much as 20% to 60% of all venous thrombosis. APCR is a consequence of the resistance of activated FV to be inactivated by activated protein C. Procoagulant activity of activated FV increases the risk of thrombosis. Hereditary APCR is almost always due to a point mutation at the nucleotide 1691 of the FV gen inducing an Arg506Glu substitution in FV molecule. This mutation is better known as FV Leiden. Heterocygous carriers of FV Leiden have a thrombotic risk 5 to 10 times higher than general population while the risk for the homocygote state is increased 50 to 100-fold. When activated PC is added to plasma from patients with FV Leiden, this last resists the anticoagulant effect of activated PC. Therefore, thrombin production is not inhibited. This phenomenon is called APCR. The functional test evaluates the partially activated thromboplastin time (aPTT) in a plasma sample before and after adding activated PC. The result is reported as a standardized sensibility index: aPTT post-activated PC/aPTT pre-activated PC. The conclusions of this national reunion pretend to optimize the available resources in our country in order to allow a wide and less-expensive diagnosis of patients with thrombosis. more...
- Published
- 2003
117. Refractory anemia with excess of blasts: increased survival when treated with cyclophosphamide, methotrexate and 6-mercaptopurine
- Author
-
Rafael Hurtado, Abraham Majluf-Cruz, Florencia Vargas-Vorackova, and Juan Labardini-Méndez
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Side effect ,Cyclophosphamide ,Adolescent ,medicine.medical_treatment ,Gastroenterology ,chemistry.chemical_compound ,Leukocyte Count ,Anabolic Agents ,Internal medicine ,medicine ,Humans ,Aged ,Aged, 80 and over ,Chemotherapy ,Anemia, Refractory, with Excess of Blasts ,business.industry ,Mercaptopurine ,Platelet Count ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Methotrexate ,chemistry ,Oxymetholone ,Antifolate ,Drug Therapy, Combination ,Female ,business ,Refractory anemia with excess of blasts ,Immunosuppressive Agents ,medicine.drug - Abstract
Owing to the lack of efficacious treatments for refractory anemia with an excess of blasts (RAEB), evaluation of other therapeutic strategies is necessary, especially in elderly patients. We report herein our experience with an oral triple drug regimen with cyclophosphamide 200 mg/m 2 and methotrexate 20 mg/m 2 once a week, and 6-mercaptopurine 50 mg/m 2 daily for the treatment of RAEB. Eighteen patients with a median age of 62 yr (range 17-80) received a triple drug regimen (TDR), and they were compared with 6 patients who received oxymetholone (2 mg/m 2 /d) and 9 who received supportive therapy only. Partial response was achieved in 45% of patients receiving TDR. In 77% of patients treated with TDR the number of bone marrow blasts decreased to more...
- Published
- 1999
118. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism
- Author
-
George A. Omburo, Wen-Hui Zhu, and Abraham Majluf-Cruz
- Subjects
IBMX ,4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone ,Phosphodiesterase Inhibitors ,Pyridones ,Phosphodiesterase 3 ,Apoptosis ,HL-60 Cells ,Biology ,General Biochemistry, Genetics and Molecular Biology ,chemistry.chemical_compound ,3',5'-Cyclic-GMP Phosphodiesterases ,1-Methyl-3-isobutylxanthine ,medicine ,Cyclic AMP ,Humans ,General Pharmacology, Toxicology and Pharmaceutics ,Cyclic GMP ,Rolipram ,Forskolin ,Trequinsin ,Phosphodiesterase ,General Medicine ,Pyrrolidinones ,Cell biology ,chemistry ,3',5'-Cyclic-AMP Phosphodiesterases ,Second messenger system ,Female ,PDE10A ,medicine.drug ,Milrinone - Abstract
Phosphodiesterases (PDEs) are responsible for the hydrolysis of cAMP and cGMP which act as intracellular second messengers in a variety of cellular functions. In this paper we report that PDE3 and PDE4 were two dominant classes of PDEs expressed in HL60 cells. The influence of specific PDE inhibitors on apoptosis in HL60 cells was studied. The non-specific inhibitor IBMX and PDE3 specific inhibitors (milrinone and trequinsin) did not promote apoptosis. They inhibited apoptosis induced by paclitaxel or thapsigargin. However, PDE4 specific inhibitors (rolipram and RO-20-1724) promoted apoptosis within 5 h. In HL60 cells, other cAMP-eliciting reagents (8-bromo-cAMP, Sp-cAMP and forskolin) also inhibited apoptosis, while cell-permeable cGMP analogs did not affect apoptosis. Therefore, IBMX and PDE3 specific inhibitors may prevent HL60 cells from apoptosis by increasing intracellular cAMP. However, apoptosis induced by PDE4 specific inhibitors is not likely due to increased cAMP level. These results suggest that rolipram and RO-20-1724 promoted apoptosis in HL60 cells through cAMP-independent mechanism. more...
- Published
- 1998
119. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats
- Author
-
Abraham Majluf-Cruz, Antoni Stadnicki, Charles A. Kettner, Robert W. Colman, Ryan Balfour Sartor, Ram Janardham, and Albert Adam
- Subjects
Boron Compounds ,medicine.medical_specialty ,Arthritis ,Inflammation ,Peptidoglycan ,Systemic inflammation ,Granulomatous Disease, Chronic ,Biochemistry ,Gastroenterology ,Inflammatory bowel disease ,Internal medicine ,Genetics ,Medicine ,Animals ,Humans ,Leukocytosis ,Enzyme Inhibitors ,Molecular Biology ,Factor XI ,Enterocolitis ,business.industry ,Kininogens ,Albumin ,Prekallikrein ,Kallikrein ,medicine.disease ,Rats ,Disease Models, Animal ,Intestinal Diseases ,Rats, Inbred Lew ,Female ,Kallikreins ,Disease Susceptibility ,medicine.symptom ,business ,Oligopeptides ,Biotechnology ,Acute-Phase Proteins - Abstract
The kallikrein-kinin (K-K) (contact) system is activated during acute and chronic relapsing phases of enterocolitis induced in genetically susceptible Lewis rats by intramural injection of peptidoglycan-polysaccharide (PG-APS). Using the selective plasma kallikrein inhibitor P8720, we investigate whether activation of the K-K system plays a primary role in chronic granulomatous intestinal and systemic inflammation in this model. Group I (negative control) received human serum albumin intramurally. Group II (treatment) received PG-APS intramurally and P8720 orally. Group III (positive control) received PG-APS intramurally and albumin orally. P8720 attenuated the consumption of the contact proteins, high molecular weight kininogen (P more...
- Published
- 1998
120. SERUM ERYTHROPOIETIN LEVELS IN KIDNEY DONORS AFTER RENAL TRANSPLANTATION
- Author
-
Reina Rosas Romero, Abraham Majluf-Cruz, Florencia Vargas-Vorackova, Josefina Alberú, Irma Isordia-Salas, and Ricardo Correa-Rotter
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Hemorrhage ,Kidney ,Nephrectomy ,Blood cell ,Hemoglobins ,Basal (phylogenetics) ,Internal medicine ,Living Donors ,medicine ,Humans ,False Positive Reactions ,Prospective Studies ,Organ donation ,Erythropoietin ,Transplantation ,business.industry ,Middle Aged ,medicine.disease ,Kidney Transplantation ,Tissue Donors ,medicine.anatomical_structure ,Endocrinology ,Kidney Failure, Chronic ,Female ,business ,Follow-Up Studies ,Kidney disease ,medicine.drug - Abstract
Background. Renal transplantation is the treatment of choice for many patients with end-stage renal disease. In the donor, renal excretory function is not affected after nephrectomy; however, little is known about other functions such as erythropoietin production. We studied the erythropoietin production in renal donors after nephrectomy. Methods. We included healthy individuals fulfilling the criteria for kidney donation. Blood samples were collected before and monthly from 1 to 6 months after nephrectomy. Complete blood cell counts and erythropoietin were assayed. Results. Eight kidney donors were studied. A significant increase in erythropoietin levels was observed during the first 3 months, but no difference was observed by the 4th month as compared with basal values. Conclusions. Erythropoietin production rose during the first 3 months after nephrectomy. However, erythropoietin was normal by the 4th month. Unchanged hemoglobin levels may suggest that the compensatory production of erythropoietin could participate in the preservation of an adequate physiological status of the donor after nephrectomy. more...
- Published
- 2000
- Full Text
- View/download PDF
121. Response to Factor V Leiden in Mexico
- Author
-
Abraham Majluf-Cruz
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Factor V Leiden ,Medicine ,Hematology ,General Medicine ,business ,medicine.disease - Published
- 2009
- Full Text
- View/download PDF
122. Arterial and venous thrombosis associated to combined deficiency of protein C and antithrombin III
- Author
-
Leticia Sansores-Garcia and Abraham Majluf-Cruz
- Subjects
medicine.medical_specialty ,Venous thrombosis ,Text mining ,business.industry ,Internal medicine ,Antithrombin ,medicine ,Hematology ,medicine.disease ,business ,Gastroenterology ,Protein C ,medicine.drug - Published
- 1998
- Full Text
- View/download PDF
123. AIDS-ASSOCIATED LYMPHOMA TREATED WITH A MODIFIED MACOP-B REGIMEN WITH A WEEKLY GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) RESCUE
- Author
-
Abraham Majluf-Cruz, Leopoldo Nieto-Cisneros, and Germán Luna-Castaños
- Subjects
Oncology ,medicine.medical_specialty ,Infectious Diseases ,Acquired immunodeficiency syndrome (AIDS) ,business.industry ,Internal medicine ,medicine ,Pharmacology (medical) ,MACOP-B regimen ,medicine.disease ,business ,Granulocyte colony-stimulating factor ,Lymphoma - Published
- 1999
- Full Text
- View/download PDF
124. AIDS-related pure red cell aplasia
- Author
-
Germ aacute Luna-Castaños, Abraham Majluf-Cruz, and Leopoldo Nieto-Cisneros
- Subjects
medicine.medical_specialty ,Acquired immunodeficiency syndrome (AIDS) ,business.industry ,medicine ,Follow up studies ,Pure red cell aplasia ,Hematology ,medicine.disease ,business ,Dermatology - Published
- 1996
- Full Text
- View/download PDF
125. Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: A prospective study
- Author
-
Miguel Angel Rodriguez-Escobedo, Jesús Hernández-Juárez, Abraham Majluf-Cruz, Gerardo Cogque-Hernandez, Rosalia Palafox-Gomez, Manuel Moreno-Hernández, Irma Isordia-Salas, Jose Fernando Moran-Perez, Xochitl Hernandez-Giron, Ethel García-Latorre, and Rubén Julián-Nacer more...
- Subjects
Leptin ,Physiology ,Transdermal Patch ,Thyroid Function Tests ,Ethinyl Estradiol ,Weight Gain ,Liver Function Tests ,Implante contraceptivo subdérmico ,Oximes ,Obstetrics and Gynaecology ,Contraceptive Agents, Female ,Insulin ,Longitudinal Studies ,Insulin-Like Growth Factor I ,Prospective cohort study ,education.field_of_study ,medicine.diagnostic_test ,C-Peptide ,Norgestrel ,Subdermal contraceptive implant ,Obstetrics and Gynecology ,Parche cutáneo anticonceptivo ,Drug Combinations ,C-Reactive Protein ,Contraception ,Female ,Adiponectin ,Contraceptive implant ,medicine.drug ,Adult ,Contraceptive skin patch ,medicine.medical_specialty ,Population ,Desogestrel ,medicine ,Humans ,Cambios metabólicos ,education ,Etonogestrel ,Mexico ,Gynecology ,business.industry ,Research ,Contracepción ,Lipid Metabolism ,Metabolic effects ,Skin patch ,Reproductive Medicine ,Metabolic changes ,Efectos metabólicos ,Liver function tests ,Lipid profile ,business - Abstract
Background The contraceptive skin patch (CSP) accepted by the U.S. FDA in 2001 includes ethinylestradiol and norelgestromine, whereas the subdermal contraceptive implant (SCI) has etonogestrel and is also approved by the FDA. In Mexico, both are now widely used for contraception but their effects on Mexican population are unknown. The objective of the study was to evaluate if these treatments induce metabolic changes in a sample of indigenous and mestizo Mexican women. Methods An observational, prospective, longitudinal, non-randomized study of women between 18 and 35 years of age assigned to CSP or SCI. We performed several laboratory tests: clinical chemistry, lipid profile, and liver and thyroid function tests. Also, serum levels of insulin, C-peptide, IGF-1, leptin, adiponectin, and C reactive protein were assayed. Results Sixty-two women were enrolled, 25 used CSP (0 indigenous; 25 mestizos) and 37 used SCI (18 indigenous; 19 mestizos). Clinical symptoms were relatively more frequent in the SCI group. Thirty-four contraceptive users gained weight without other clinical significant changes. After 4 months of treatment, significant changes were found in some biochemical parameters in both treatment groups. Most were clinically irrelevant. Interestingly, the percentage of users with an abnormal atherogenic index diminished from 75% to 41.6% after follow-up. Conclusions The CSP slightly modified the metabolic variables. Most changes were nonsignificant, whereas for SCI users changes were more evident and perhaps beneficial. Results of this attempt to evaluate the effects of contraceptives in mestizo and native-American populations show that clinical symptoms are frequent in Mexican users of CSP and SCI. Although these medications may affect some metabolic variables, these changes seem clinically irrelevant. Induction of abnormalities in other physiological pathways cannot be ruled out. more...
- Full Text
- View/download PDF
126. Mexican mestizo population sub-structure: effects on genetic and forensic statistical parameters
- Author
-
Jonathan J. Magaña, Salvador Xihuitl, María Cristina Revilla, Abraham Majluf-Cruz, Carla Santana, Julio Granados, Marco Antonio Meraz-Ríos, Rocío Gómez, Sergio Martínez-Salas, Alvaro Diaz-Badillo, Emma S. Calderón-Aranda, Gino Noris, Rosa Quezada, Gonzalo Martínez de la Escalera, and María de Lourdes Muñoz more...
- Subjects
Forensic Genetics ,Linkage disequilibrium ,Genotype ,Population ,Black People ,Paternity ,Biology ,Linkage Disequilibrium ,White People ,Gene Frequency ,Genetic variation ,Genetics ,medicine ,Humans ,Genetic Testing ,Allele ,education ,Molecular Biology ,Allele frequency ,Mexico ,Genetic testing ,education.field_of_study ,Models, Statistical ,medicine.diagnostic_test ,Models, Genetic ,General Medicine ,Genetic Loci ,Indians, North American ,Microsatellite ,Inbreeding ,Microsatellite Repeats - Abstract
Since Mexican mestizos are an admixed population, it is necessary to determine the effects that the substructure of the population has on genetic and forensic parameters. With this aim, a study was performed with 15 STR loci (CODIS plus D2S1338 and D19S433) on 1,640 unrelated Mexican mestizos. We determine allele and genotypic frequencies observing departure from Hardy-Weinberg expectation (12 out of 15 loci, with an excess of homozygotes, Fis > 0), as well as pairs of loci in an apparent linkage disequilibrium (13 of 92 loci). We conducted a test for genetic population stratification, the results show that the Mexican mestizo population is substructured into three subgroups, which are in HW and linkage equilibrium. The combination of the 15 loci in the whole population has high forensic efficiency with the capacity to genetically discriminate one individual in one quintillion (1/10(18)). Our data potentially validates the use of these 15 STR loci to establish forensic identity and parentage testing for legal purposes, and offers a powerful tool for genetic variation analysis. However, given that the population is stratified, we highly recommend applying a correction with the inbreeding coefficient in calculations of paternity and forensic studies to avoid erroneous assumptions. more...
127. Better detection of platelet aggregation in patients with metabolic syndrome using epinephrine and ADP
- Author
-
Diana Matías-Pérez, Edgar Zenteno, Socorro Pina-Canseco, Abraham Majluf-Cruz, Pedro Hernández, Miguel Angel Reyes Franco, Ruth Martínez-Cruz, Francisco Javier Rodal-Canales, Eduardo Pérez-Campos, Laura Pérez-Campos-Mayoral, Eduardo Perez-Ortega, Belem Gallegos, and Gabriel Mayoral Andrade more...
- Subjects
Platelets ,ADP ,medicine.medical_specialty ,Epinephrine ,business.industry ,Research ,Insulin ,medicine.medical_treatment ,Endocrinology, Diabetes and Metabolism ,Area under the curve ,medicine.disease ,Metabolic syndrome ,Blood pressure ,Endocrinology ,Insulin resistance ,Diabetes mellitus ,Internal medicine ,medicine ,Internal Medicine ,Platelet ,business ,medicine.drug - Abstract
Background: Patients with metabolic syndrome (MS) often have increased platelet aggregation. In order to determine which concentration detects a higher level of platelet aggregation in patients with MS, the agonists ADP and epinephrine were compared. Methods: The study included 56 subjects with MS and 53 healthy subjects. Blood pressure, weight, body-mass index, and hip-to-waist ratio were collected from all subjects. Insulin, glucose, total serum cholesterol, HDL-C, LDL-C, total triglycerides, markers of plasma atherogenicity, and indices of insulin resistance were measured in all participants. For aggregometry assays, the Born method was used. Platelets were treated with ADP and epinephrine in decreasing concentrations of 2.34, 1.17, and 0.58 μM, as well as, 11.0, 1.1, and 0.55 μM, respectively. ROC curves were plotted to define the diagnostic efficiency of epinephrine levels for MS. Results: Among healthy individuals and MS patients significant differences were observed in body weight, body-mass index, waist-circumference, levels of insulin, indices of insulin resistance, and levels of HDL-cholesterol, LDL-cholesterol and total triglycerides. There was a significant difference in the detection of increased platelet aggregation using 11.0 μM and 0.55 μM epinephrine and 0.58 μM ADP. With both agonists, ROC analysis showed an area under the curve of >0.8 for 11.0 μM epinephrine and 2.34 μM ADP. However, for MS patients, 11.0 μM epinephrine had a slightly better diagnostic efficiency than 2.34 μ MA DP. Conclusions: It was found that 11.0 μM epinephrine and 2.34 μM ADP detected better platelet aggregation in patients with MS than in healthy subject. Both concentrations detected increased platelet aggregation in patients with MS. more...
- Full Text
- View/download PDF
128. Dificultades en la clasificación del síndrome metabólico: El ejemplo de los adolescentes en México
- Author
-
Eneida Camarillo-Romero, Ma Victoria Domínguez García, Araceli Amaya-Chávez, Gerardo Huitrón-Bravo, Abraham Majluf-Cruz, and Eneida Camarillo-Romero
- Subjects
Síndrome metabólico ,México ,adolescente ,Salud - Abstract
OBJETIVO. Determinar la diferencia entre las definiciones del National Cholesterol Education Program Adult Treatment Panel (ATPIII) y de la International Diabetes Federation (IDF) para síndrome metabólico (SM) en adolescentes mexicanos. MATERIAL Y MÉTODOS. Estudio transversal en 575 adolescentes de 14 a 16 años. Se utilizaron pruebas t de Student, ji cuadrada y correlación de Spearman. RESULTADOS. La prevalencia de SM fue mayor por ATPIII (18.6%) versus IDF (8.2%) (p more...
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.